{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:23:14Z","timestamp":1792131794171,"version":"4.4.0"},"reference-count":130,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>The flavivirus genus contains several clinically important pathogens that account for tremendous global suffering. Primarily transmitted by mosquitos or ticks, these viruses can cause severe and potentially fatal diseases ranging from hemorrhagic fevers to encephalitis. The extensive global burden is predominantly caused by six flaviviruses: dengue, Zika, West Nile, yellow fever, Japanese encephalitis and tick-borne encephalitis. Several vaccines have been developed, and many more are currently being tested in clinical trials. However, flavivirus vaccine development is still confronted with many shortcomings and challenges. With the use of the existing literature, we have studied these hurdles as well as the signs of progress made in flavivirus vaccinology in the context of future development strategies. Moreover, all current licensed and phase-trial flavivirus vaccines have been gathered and discussed based on their vaccine type. Furthermore, potentially relevant vaccine types without any candidates in clinical testing are explored in this review as well. Over the past decades, several modern vaccine types have expanded the field of vaccinology, potentially providing alternative solutions for flavivirus vaccines. These vaccine types offer different development strategies as opposed to traditional vaccines. The included vaccine types were live-attenuated, inactivated, subunit, VLPs, viral vector-based, epitope-based, DNA and mRNA vaccines. Each vaccine type offers different advantages, some more suitable for flaviviruses than others. Additional studies are needed to overcome the barriers currently faced by flavivirus vaccine development, but many potential solutions are currently being explored.<\/jats:p>","DOI":"10.3390\/v15040860","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T02:58:21Z","timestamp":1679972301000},"page":"860","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["A Perspective on Current Flavivirus Vaccine Development: A Brief Review"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4991-6640","authenticated-orcid":false,"given":"Sudip Kumar","family":"Dutta","sequence":"first","affiliation":[{"name":"Artemis Bioservices, Molengraaffsingel 10, 2629 JD Delft, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Langenburg","sequence":"additional","affiliation":[{"name":"Artemis Bioservices, Molengraaffsingel 10, 2629 JD Delft, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"ref_1","unstructured":"MacLachlan, N.J., and Dubovi, E.J. (2017). Fenner\u2019s Veterinary Virology, Elsevier. [5th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1517\/17460441.2016.1160887","article-title":"New developments in flavivirus drug discovery","volume":"11","author":"Kok","year":"2016","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/bioinformatics\/17.8.754","article-title":"MRBAYES: Bayesian inference of phylogenetic trees","volume":"17","author":"Huelsenbeck","year":"2001","journal-title":"Bioinformatics"},{"key":"ref_4","unstructured":"World Health Organization (2022, December 15). Dengue and Severe Dengue. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue."},{"key":"ref_5","unstructured":"(2018). Dengue Vaccines: WHO Position Paper\u2014September 2018 Weekly Epidemiological Record, WHO."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1128\/microbiolspec.AID-0022-2014","article-title":"Dengue Antibody-Dependent Enhancement: Knowns and Unknowns","volume":"2","author":"Halstead","year":"2014","journal-title":"Microbiol. Spectr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aan6836","article-title":"Antibody-dependent enhancement of severe dengue disease in humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"ref_8","first-page":"S66","article-title":"The Zika Virus Infection in Pregnancy: Review and Implications for Research and Care of Women and Infants in Affected Areas","volume":"37","author":"Zorrilla","year":"2018","journal-title":"Puerto Rico Health Sci. J."},{"key":"ref_9","unstructured":"WHO (2022, December 10). Countries and Territories with Current or Previous Zika Virus Transmission. Updated February 2022. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/documents\/emergencies\/zika\/countries-with-zika-and-vectors-table_february-2022.pdf."},{"key":"ref_10","unstructured":"(2022, February 08). Zika Epidemiology Update\u2014February 2022. Available online: https:\/\/www.who.int\/publications\/m\/item\/zika-epidemiology-update---february-2022."},{"key":"ref_11","unstructured":"(2022, December 10). Dengue around the World\u2014CDC, Available online: https:\/\/www.cdc.gov\/dengue\/areaswithrisk\/around-the-world.html."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Habarugira, G., Suen, W.W., Hobson-Peters, J., Hall, R.A., and Bielefeldt-Ohmann, H. (2020). West Nile Virus: An Update on Pathobiology, Epidemiology, Diagnostics, Control and \u201cOne Health\u201d Implications. Pathogens, 9.","DOI":"10.3390\/pathogens9070589"},{"key":"ref_13","unstructured":"(2022, December 15). West Nile Virus\u2014CDC, Available online: https:\/\/www.cdc.gov\/westnile\/index.html."},{"key":"ref_14","unstructured":"(2022, December 10). World Health Organization (2 September 2022). Disease Outbreak News; Yellow Fever in East, West, and Central Africa. Available online: https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON405."},{"key":"ref_15","unstructured":"(2022, December 10). Centers for Disease Control and Prevention (2022) Geographic Distribution of Japanese Encephalitis Virus, Available online: https:\/\/www.cdc.gov\/japaneseencephalitis\/maps\/index.html."},{"key":"ref_16","unstructured":"(2022, December 10). Japanese Encephalitis Virus (JEV), Available online: https:\/\/www.health.gov.au\/health-alerts\/japanese-encephalitis-virus-jev\/about#current-status."},{"key":"ref_17","unstructured":"(2022, December 15). Tick-Borne Encephalitis. Available online: https:\/\/www.who.int\/health-topics\/tick-borne-encephalitis#tab=tab_1."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Radzi\u0161auskien\u0117, D., Urbonien\u0117, J., Kaubrys, G., Andru\u0161kevi\u010dius, S., Jatu\u017eis, D., Matulyt\u0117, E., and \u017dvirblyt\u0117-Skrebutien\u0117, K. (2020). The epidemiology, clinical presentation, and predictors of severe Tick-borne encephalitis in Lithuania, a highly endemic country: A retrospective study of 1040 patients. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0241587"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.tim.2018.05.012","article-title":"Yellow Fever Virus: Knowledge Gaps Impeding the Fight Against an Old Foe","volume":"26","author":"Douam","year":"2018","journal-title":"Trends Microbiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.chom.2021.12.009","article-title":"Genotype-specific features reduce the susceptibility of South American yellow fever virus strains to vaccine-induced antibodies","volume":"30","author":"Haslwanter","year":"2022","journal-title":"Cell Host Microbe"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10832","DOI":"10.1038\/ncomms10832","article-title":"Vector-free transmission and persistence of Japanese encephalitis virus in pigs","volume":"7","author":"Ricklin","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s11908-018-0635-8","article-title":"Evolving Epidemiology of Japanese Encephalitis: Implications for Vaccination","volume":"20","author":"Caldwell","year":"2018","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_23","unstructured":"(2022, December 15). Weekly Updates: 2022 West Nile Virus Transmission Season. Available online: https:\/\/www.ecdc.europa.eu\/en\/west-nile-fever\/surveillance-and-disease-data\/disease-data-ecdc."},{"key":"ref_24","unstructured":"European Centre for Disease Prevention and Control (2022). ECDC. Annual Epidemiological Report for 2022, ECDC."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1146\/annurev.mi.44.100190.003245","article-title":"Flavivirus genome organization, expression, and replication","volume":"44","author":"Chambers","year":"1990","journal-title":"Annu. Rev. Microbiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1021\/acs.chemrev.7b00719","article-title":"Biochemistry and Molecular Biology of Flaviviruses","volume":"118","author":"Barrows","year":"2018","journal-title":"Chem. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.coviro.2012.12.001","article-title":"Flaviviruses: Braking the entering","volume":"3","author":"Pierson","year":"2013","journal-title":"Curr. Opin. Virol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.chom.2009.04.001","article-title":"Pathogenesis of Flavivirus Infections: Using and Abusing the Host Cell","volume":"5","author":"Mazzon","year":"2009","journal-title":"Cell Host Microbe"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"206","DOI":"10.15252\/embr.201745302","article-title":"The bright and the dark side of human antibody responses to flaviviruses: Lessons for vaccine design","volume":"19","author":"Rey","year":"2018","journal-title":"EMBO Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41590-018-0210-3","article-title":"The immune response against flaviviruses","volume":"19","author":"Mongkolsapaya","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1073\/pnas.1200566109","article-title":"Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions","volume":"109","author":"Smith","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.tibs.2021.03.005","article-title":"How NS1 Antibodies Prevent Severe Flavivirus Disease","volume":"46","author":"Ooi","year":"2021","journal-title":"Trends Biochem. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s007050050127","article-title":"The dengue virus nonstructural-1 protein (NS1) generates antibodies to common epitopes on human blood clotting, integrin\/adhesin proteins and binds to human endothelial cells: Potential implications in haemorrhagic fever pathogenesis","volume":"142","author":"Falconar","year":"1997","journal-title":"Arch. Virol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"304ra141","DOI":"10.1126\/scitranslmed.aaa3787","article-title":"Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination","volume":"7","author":"Beatty","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1128\/CMR.00035-09","article-title":"Dengue Virus Pathogenesis: An Integrated View","volume":"22","author":"Martina","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.vaccine.2014.01.040","article-title":"A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available","volume":"32","author":"Ishikawa","year":"2014","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e00947-19","DOI":"10.1128\/JVI.00947-19","article-title":"Protein Vaccination Directs the CD4 + T Cell Response toward Shared Protective Epitopes That Can Be Recalled after Influenza Virus Infection","volume":"93","author":"Rattan","year":"2019","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4553","DOI":"10.1038\/s41467-019-12444-7","article-title":"Rapid selection and identification of functional CD8+ T cell epitopes from large peptide-coding libraries","volume":"10","author":"Sharma","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20161533","article-title":"Differentiation of germinal center B cells into plasma cells is initiated by high-affinity antigen and completed by Tfh cells","volume":"214","author":"Suan","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.immuni.2007.07.009","article-title":"Germinal-Center Organization and Cellular Dynamics","volume":"27","author":"Allen","year":"2007","journal-title":"Immunity"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A guide to vaccinology: From basic principles to new developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Dai, X., Xiong, Y., Li, N., and Jian, C. (2022, December 21). Vaccine Types. 2019. Vaccines\u2014The History and Future. IntechOpen. Available online: https:\/\/www.intechopen.com\/chapters\/undefined\/state.item.id.","DOI":"10.5772\/intechopen.84626"},{"key":"ref_43","unstructured":"(2023, January 31). Approved Vaccine Products|FDA, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/approved-vaccine-products."},{"key":"ref_44","unstructured":"(2022, December 10). WHO Guidelines on Non-Clinical Evaluation of Vaccines, Annex 1, TRS No 927. Available online: https:\/\/www.who.int\/publications\/m\/item\/nonclinical-evaluation-of-vaccines-annex-1-trs-no-927."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1586\/14760584.4.6.855","article-title":"Ensuring the quality, potency and safety of vaccines during preclinical development","volume":"4","author":"Wolf","year":"2005","journal-title":"Expert Rev. Vaccines"},{"key":"ref_46","unstructured":"(2023, January 31). World Health Organization (2003) Guidelines on Nonclinical Evaluation of Vaccines. World Health Organization, Geneva. Available online: https:\/\/www.impfkritik.de\/upload\/pdf\/wirksamkeitsnachweis\/WHO-2003.pdf."},{"key":"ref_47","unstructured":"World Health Organization (1995). Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Products, WHO."},{"key":"ref_48","unstructured":"(2023, January 31). Vaccine Development\u2014101|FDA, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/development-approval-process-cber\/vaccine-development-101."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3810\/pgm.2011.09.2475","article-title":"Key Concepts of Clinical Trials: A Narrative Review","volume":"123","author":"Umscheid","year":"2011","journal-title":"Postgrad. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","article-title":"Live attenuated vaccines: Historical successes and current challenges","volume":"479\u2013480","author":"Minor","year":"2015","journal-title":"Virology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1016\/j.vaccine.2013.05.096","article-title":"Live attenuated tularemia vaccines: Recent developments and future goals","volume":"31","author":"Marohn","year":"2013","journal-title":"Vaccine"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5951","DOI":"10.1016\/j.vaccine.2017.03.032","article-title":"Yellow fever live attenuated vaccine: A very successful live attenuated vaccine but still we have problems controlling the disease","volume":"35","author":"Barrett","year":"2017","journal-title":"Vaccine"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1128\/JVI.02273-08","article-title":"Live Chimeric and Inactivated Japanese Encephalitis Virus Vaccines Differ in Their Cross-Protective Values against Murray Valley Encephalitis Virus","volume":"83","author":"Lobigs","year":"2009","journal-title":"J. Virol."},{"key":"ref_54","first-page":"635","article-title":"The Double-Edged Sword: How Evolution Can Make or Break a Live-Attenuated Virus Vaccine","volume":"4","author":"Hanley","year":"2011","journal-title":"Evolution"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1126\/science.1155761","article-title":"Virus attenuation by genome-scale changes in codon pair bias","volume":"320","author":"Coleman","year":"2008","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nbt.1635","article-title":"Rationalizing the development of live attenuated virus vaccines","volume":"28","author":"Lauring","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11908-017-0566-9","article-title":"Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day","volume":"19","author":"Collins","year":"2017","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.2147\/DDDT.S99600","article-title":"Yellow fever vaccine-associated viscerotropic disease: Current perspectives","volume":"10","author":"Thomas","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1016\/j.vaccine.2014.03.074","article-title":"Characterization of live-attenuated Japanese encephalitis vaccine virus SA14-14-2","volume":"32","author":"Yang","year":"2014","journal-title":"Vaccine"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1586\/erv.10.139","article-title":"IMOJEV\u00ae: A Yellow fever virus-based novel Japanese encephalitis vaccine","volume":"9","author":"Appaiahgari","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.1016\/j.vaccine.2015.09.053","article-title":"Next generation dengue vaccines: A review of the preclinical development pipeline","volume":"33","author":"Vannice","year":"2015","journal-title":"Vaccine"},{"key":"ref_62","first-page":"351","article-title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in na\u00efve and dengue exposed individuals","volume":"215","author":"Henein","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia\u00ae: Development to deployment","volume":"15","author":"Thomas","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"6355","DOI":"10.1016\/j.vaccine.2017.09.089","article-title":"Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age","volume":"35","author":"Halstead","year":"2017","journal-title":"Vaccine"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1016\/j.vaccine.2015.09.105","article-title":"Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine","volume":"33","author":"Precioso","year":"2015","journal-title":"Vaccine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/14760584.2016.1128328","article-title":"A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone","volume":"15","author":"Osorio","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1473-3099(17)30166-4","article-title":"Safety and immunogenicity of one versus two doses of Takeda\u2019s tetravalent dengue vaccine in children in Asia and Latin America: Interim results from a phase 2, randomised, placebo-controlled study","volume":"17","author":"Tricou","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"CYD-TDV Dengue Vaccine Working Group. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease","volume":"373","author":"Hadinegoro","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/S0042-6822(03)00450-1","article-title":"Molecularly engineered live-attenuated chimeric West Nile\/dengue virus vaccines protect rhesus monkeys from West Nile virus","volume":"314","author":"Pletnev","year":"2003","journal-title":"Virology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"Monath","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1586\/erv.12.38","article-title":"Inactivated virus vaccines from chemistry to prophylaxis: Merits, risks and challenges","volume":"11","author":"Delrue","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"ref_72","first-page":"103","article-title":"Review of accidents caused by incomplete inactivation of viruses","volume":"81","author":"Brown","year":"1993","journal-title":"Dev. Biol. Stand."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1016\/j.vaccine.2009.12.080","article-title":"Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: Using PRNT50 as an endpoint for immunogenicity","volume":"28","author":"Reisler","year":"2010","journal-title":"Vaccine"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.vaccine.2010.10.016","article-title":"Adverse event reports following Japanese encephalitis vaccination in the United States, 1999\u20132009","volume":"29","author":"Lindsey","year":"2010","journal-title":"Vaccine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1099\/vir.0.011437-0","article-title":"Tick-borne encephalitis virus\u2014A review of an emerging zoonosis","volume":"90","author":"Mansfield","year":"2009","journal-title":"J. Gen. Virol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"7307","DOI":"10.1016\/j.vaccine.2011.07.089","article-title":"Prevention of tick-borne encephalitis by FSME-IMMUN\u00ae vaccines: Review of a clinical development programme","volume":"29","author":"Poellabauer","year":"2011","journal-title":"Vaccine"},{"key":"ref_77","unstructured":"Plotkin, S.A., Orenstein, W.A., Offit, P.A., and Edwards, K.M. (2018). Plotkin\u2019s Vaccines, Elsevier. [7th ed.]."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"698","DOI":"10.4269\/ajtmh.14-0268","article-title":"An Adjuvanted, Tetravalent Dengue Virus Purified Inactivated Vaccine Candidate Induces Long-Lasting and Protective Antibody Responses Against Dengue Challenge in Rhesus Macaques","volume":"92","author":"Fernandez","year":"2015","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0140-6736(17)33106-9","article-title":"Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: Phase 1, randomised, double-blind, placebo-controlled clinical trials","volume":"391","author":"Modjarrad","year":"2018","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/S1473-3099(20)30733-7","article-title":"Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in healthy adults: An observer-blind, randomised, phase 1 trial","volume":"21","author":"Han","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"16509","DOI":"10.1038\/s41598-018-34735-7","article-title":"Purified Inactivated Zika Vaccine Candidates Afford Protection against Lethal Challenge in Mice","volume":"8","author":"Baldwin","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","article-title":"An Inactivated Cell-Culture Vaccine against Yellow Fever","volume":"364","author":"Monath","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","article-title":"Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity","volume":"28","author":"Monath","year":"2010","journal-title":"Vaccine"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/cmdc.201200487","article-title":"Modern Subunit Vaccines: Development, Components, and Research Opportunities","volume":"8","author":"Moyle","year":"2013","journal-title":"Chemmedchem"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1080\/21645515.2018.1546523","article-title":"Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: Results of a Phase I randomized clinical trial in flavivirus-na\u00efve adults","volume":"15","author":"Manoff","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1128\/CVI.00119-09","article-title":"Immunogenicity and Protective Efficacy of a Recombinant Subunit West Nile Virus Vaccine in Rhesus Monkeys","volume":"16","author":"Lieberman","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"36","DOI":"10.29245\/2578-3009\/2018\/2.1118","article-title":"Advances and challenges in enveloped virus-like particle (VLP)-based vaccines","volume":"2","author":"Dai","year":"2018","journal-title":"J. Immunol. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.tibtech.2019.03.013","article-title":"Production and Biomedical Application of Flavivirus-like Particles","volume":"37","author":"Krol","year":"2019","journal-title":"Trends Biotechnol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.nbt.2017.07.010","article-title":"Production of virus-like particles for vaccines","volume":"39 Pt B","author":"Fuenmayor","year":"2017","journal-title":"New Biotechnol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Cabral-Miranda, G., Lim, S.M., Mohsen, M.O., Pobelov, I.V., Roesti, E.S., Heath, M.D., Skinner, M.A., Kramer, M.F., Martina, B.E.E., and Bachmann, M.F. (2019). Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines, 7.","DOI":"10.3390\/vaccines7030072"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.4049\/jimmunol.1600927","article-title":"A Tetravalent Formulation Based on Recombinant Nucleocapsid-like Particles from Dengue Viruses Induces a Functional Immune Response in Mice and Monkeys","volume":"197","author":"Gil","year":"2016","journal-title":"J. Immunol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1016\/j.vaccine.2021.10.049","article-title":"Flavivirus vaccines: Virus-like particles and single-round infectious particles as promising alternatives","volume":"39","author":"Palomares","year":"2021","journal-title":"Vaccine"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3389\/fimmu.2018.01963","article-title":"New Vaccine Technologies to Combat Outbreak Situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_94","first-page":"385","article-title":"General Considerations on the Biosafety of Virus-derived Vectors Used in Gene Therapy and Vaccination","volume":"13","author":"Akker","year":"2013","journal-title":"Curr. Gene Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/j.vaccine.2016.04.060","article-title":"Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains","volume":"34","author":"Condit","year":"2016","journal-title":"Vaccine"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e01485-18","DOI":"10.1128\/JVI.01485-18","article-title":"A Measles Virus-Based Vaccine Candidate Mediates Protection against Zika Virus in an Allogeneic Mouse Pregnancy Model","volume":"93","author":"Bodmer","year":"2019","journal-title":"J. Virol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1080\/21645515.2015.1094595","article-title":"Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production","volume":"12","author":"Kobe","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1016\/j.vaccine.2011.03.002","article-title":"Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses","volume":"29","author":"Li","year":"2011","journal-title":"Vaccine"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e02482-20","DOI":"10.1128\/JVI.02482-20","article-title":"A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses","volume":"95","author":"Wollner","year":"2021","journal-title":"J. Virol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.biotechadv.2017.09.004","article-title":"Zika virus structural biology and progress in vaccine development","volume":"36","author":"Lin","year":"2018","journal-title":"Biotechnol. Adv."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"e6185","DOI":"10.7717\/peerj.6185","article-title":"Application of built-in adjuvants for epitope-based vaccines","volume":"6","author":"Lei","year":"2019","journal-title":"PeerJ"},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Hobernik, D., and Bros, M. (2018). DNA Vaccines-How Far from Clinical Use?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113605"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"7261","DOI":"10.1016\/j.vaccine.2011.07.019","article-title":"Development of dengue DNA vaccines","volume":"29","author":"Danko","year":"2011","journal-title":"Vaccine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.addr.2021.01.003","article-title":"Advances in gene-based vaccine platforms to address the COVID-19 pandemic","volume":"170","author":"Pushparajah","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF00870272","article-title":"DNA vaccines: Safety and efficacy issues","volume":"19","author":"Klinman","year":"1997","journal-title":"Springer Semin. Immunopathol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1517\/17425247.2010.538047","article-title":"Vaxfectin: A versatile adjuvant for plasmid DNA- and protein-based vaccines","volume":"7","author":"Sullivan","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"849","DOI":"10.4269\/ajtmh.17-0416","article-title":"Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial","volume":"98","author":"Danko","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/infdis\/jir054","article-title":"A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial","volume":"203","author":"Ledgerwood","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1126\/science.aai9137","article-title":"Rapid development of a DNA vaccine for Zika virus","volume":"354","author":"Dowd","year":"2016","journal-title":"Science"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"COVE Study Group. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nri780","article-title":"Ethical issues for vaccines and immunization","volume":"2","author":"Ulmer","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"ref_113","first-page":"781","article-title":"Dengue virus (DENV)-specific antibodies enhance Brazilian Zika virus (ZIKV) infection","volume":"215","author":"Castanha","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1016\/j.vaccine.2012.04.067","article-title":"Viscerotropic disease: Case definition and guidelines for collection, analysis, and presentation of immunization safety data","volume":"30","author":"Gershman","year":"2012","journal-title":"Vaccine"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1128\/JVI.78.22.12497-12507.2004","article-title":"ChimeriVax-West Nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy","volume":"78","author":"Arroyo","year":"2004","journal-title":"J. Virol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/s41467-018-03337-2","article-title":"A systematic approach to the development of a safe live attenuated Zika vaccine","volume":"9","author":"Kwek","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.4269\/ajtmh.16-0634","article-title":"Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States","volume":"96","author":"Schmidt","year":"2017","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1590\/S0100-879X2012007500142","article-title":"Recombinant vaccines and the development of new vaccine strategies","volume":"45","author":"Nascimento","year":"2012","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/infdis\/jiu648","article-title":"Raising Expectations for Subunit Vaccine","volume":"211","author":"Schiller","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4811","DOI":"10.7150\/thno.35919","article-title":"Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization","volume":"9","author":"Lin","year":"2019","journal-title":"Theranostics"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1086\/517613","article-title":"A West Nile Virus Recombinant Protein Vaccine That Coactivates Innate and Adaptive Immunity","volume":"195","author":"McDonald","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1128\/CVI.00770-14","article-title":"Immunogenicity and Efficacy of Flagellin-Envelope Fusion Dengue Vaccines in Mice and Monkeys","volume":"22","author":"Liu","year":"2015","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"8268","DOI":"10.1016\/j.vaccine.2010.10.009","article-title":"Safety and immunogenicity of a recombinant hemagglutinin influenza\u2013flagellin fusion vaccine (VAX125) in healthy young adults","volume":"28","author":"Treanor","year":"2010","journal-title":"Vaccine"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1016\/j.vaccine.2011.05.001","article-title":"Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza\u2013flagellin fusion vaccine (VAX125, STF2.HA1 SI)","volume":"29","author":"Taylor","year":"2011","journal-title":"Vaccine"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus\u2013like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Pardy, R.D., and Richer, M.J. (2019). Protective to a T: The Role of T Cells during Zika Virus Infection. Cells, 8.","DOI":"10.3390\/cells8080820"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1016\/j.vaccine.2019.06.083","article-title":"Enhanced immunogenicity and protective efficacy of a tetravalent dengue DNA vaccine using electroporation and intradermal delivery","volume":"37","author":"Williams","year":"2019","journal-title":"Vaccine"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7774\/cevr.2015.4.1.1","article-title":"Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: Vaccine-platforms for the battle against infectious diseases","volume":"4","author":"Grunwald","year":"2015","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1080\/21645515.2017.1330236","article-title":"Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity","volume":"13","author":"Suschak","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/1535370216643771","article-title":"Micro- and nanoparticulates for DNA vaccine delivery","volume":"241","author":"Farris","year":"2016","journal-title":"Exp. Biol. Med."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/4\/860\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:04:36Z","timestamp":1760123076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/4\/860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":130,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["v15040860"],"URL":"https:\/\/doi.org\/10.3390\/v15040860","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]}}}